Skip to main content

Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications. 2023. 15(2): 382. PMID: 36672331.

  • Yu, L., Davis, I.J. and Liu, P.

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. 2021. Seminars in Cancer Biology. doi: 10.1016/j.semcancer.2021.06.019. PMID: 34175443.

  • Yu, L., Jessica Wei and Liu, P.

Cytosolic DNA sensing by cGAS: regulation, function and human diseases. 2021. Signal Transduction and Targeted Therapy. 6(1): 170. PMID: 33927185.

  • Yu, L. and Liu, P.

Experimental Approaches in Delineating mTOR Signaling. 2020. Genes. 11(7):738. PMID: 32630768.

  • Qian, J., Su, S., and Liu, P.

Roles of ubiquitination and SUMOylation in DNA damage response. 2019. Current Issues in Molecular Biology. 35:59-84. PMID: 31422933.

  • Su, S., Zhang, Y., and Liu, P.

Beyond growth signaling: apoptotic sensor MERTK activates AKT by a novel mechanism. 2019. Molecular and Cellular Oncology. doi:10.1080/23723556.2019.1611161.

  • Zhang, Y., Earp, H.S.#, and Liu, P.#

Control of mTOR signaling by ubiquitin. 2019. Oncogene. doi: 10.1038/s41388-019-0713-x.

  • Jiang, Y., Su, S., Zhang, Y., Qian, J., and Liu, P.

Akt Promotes Tumorigenesis in Part through Modulating Genomic Instability via Phosphorylating XLF. 2015. Nucleus. doi: 10.1080/19491034.2015.1074365.

  • Gan, W.*, Liu, P.* and Wei, W. (*co-first author)

Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. 2015. Int J Mol Sci. 16(11):26880-913.

  • Kim, B.M., Hong, Y., Lee, S., Liu, P., Lim, J.H., Lee, Y.H., Lee, T.H., Chang, K.T. and Hong, Y.

Cell cycle status dictates effectiveness of rapamycin. 2015. Cell Cycle. 30:1-2.

  • Gan, W.*, Liu, P.* and Wei, W. (*co-first author)

mTOR signaling in tumorigenesis. 2014. BBA Reviews on Cancer. 1846(2):638-54.

  • Kai, Xu., Liu, P.# and Wei, W.# (#co-corresponding author)

Roles of F-box proteins in cancer. 2014. Nature Reviews Cancer. 14(4): 233-247.

  • Wang, Z.*, Liu, P.*, Inuzuka, H. and Wei, W. (*co-first author)

Phosphorylation of Akt at the C-terminal tail triggers Akt Activation. 2014. Cell Cycle. 13(14): 2162-2164.

  • Liu, P.*, Wang, Z.* and Wei, W. (*co-first author)

Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity. 2014. Protein Cell. 5(3): 171-177.

  • Liu, P., Guo, J., Gan, W. and Wei, W.

Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2. 2012. Oncotarget. 3(11): 1294-1300.

  • Wang, Z., Inuzuka, H., Zhong, J., Liu, P., Sarkar, F. H., Sun, Y. and Wei, W.

DEPTOR ubiquitination and destruction by SCFß-TRCP. 2012. American Journal of Physiology-Endocrinology and Metabolism. 303(2): E163-169.

  • Wang, Z., Zhong, J., Gao, D., Inuzuka, H., Liu, P. and Wei, W.

Skp2: A novel potential therapeutic target for prostate cancer. 2012. Biochimica et Biophysica Acta. 1825 (1): 11-17.

  • Wang, Z., Gao, D., Fukushima, H., Inuzuka, H., Liu, P., Wan, L., Sarkar, F.H. and Wei, W.

Skp2 is a promising therapeutic target in breast cancer. 2012. Frontiers in Molecular and Cellular Oncology. 1: 57.

  • Wang, Z., Fukushima, H., Inuzuka, H., Wan, L., Liu, P., Gao, D. and Wei, W.

Cdc20: a potential novel therapeutic target for cancer treatment. 2012. Current Pharmaceutical Design. 19(18): 3210-3214.

  • Wang, Z., Wan, L., Zhong, J., Inuzuka, H., Liu, P., Sarkar, F.H. and Wei, W.

The two faces of FBW7 in cancer drug resistance. 2011. BioEssays. 33(11): 851-859.

  • Wang, Z., Fukushima, H., Gao, D., Inuzuka, H., Wan, L., Lau, A.W., Liu, P. and Wei, W.

Mcl-1 ubiquitination and destruction. 2011. Oncotarget. 2(3): 239-244

  • Inuzuka, H., Fukushima, H., Shaik, S., Liu, P., Lau, A.W. and Wei, W.